Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

BMJ

Volumn 329, Issue 7460, 2004, Pages 253-

  Svendsen, Kristina B ^a   Jensen, Troels S ^a   Bach, Flemming W ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; DRONABINOL; PLACEBO;

ABDOMINAL PAIN; ADULT; ANALGESIA; ANOREXIA; ARTICLE; BALANCE DISORDER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; DRUG SCREENING; EUPHORIA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERACTIVITY; MALE; MENTAL DISEASE; MENTAL HEALTH; MIGRAINE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NERVOUSNESS; NEUROPATHIC PAIN; NEUROTOXICITY; OUTPATIENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SLEEP DISORDER; SPEECH DISORDER; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, NON-NARCOTIC; CANNABINOIDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PAIN; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 4043096916     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.38149.566979.AE     Document Type: Article

References (49)

1. Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994; 58: 89–93.
2. Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984; 41: 1270–2.
3. Moulin DE, Foley KM, Ebers GC Pain syndromes in multiple sclerosis. Neurology 1988; 38: 1830–4.
4. Rae-Grant AD, Eckert NJ, Bartz S, Reed JF. Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity. Mult Scler 1999; 5: 179–83.
5. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991; 84: 197–200.
6. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 2003; 60: 1089–94.
7. Boivie J Central pain. In: Wall PD, Melzack R,eds. Textbook of pain. New York: Churchill Livingstone, 1999: 879–914.
8. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76: 189–99.
9. Martin WJ, Loo CM, Basbaum AI. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999; 82: 199–205.
10. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001; 133: 586–94.
11. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, et al. The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92: 91–100.
12. Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, Simone DA. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001; 93: 303–15.
13. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; 102: 283–8.
14. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111–9.
15. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003; 103: 175–86.
16. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 1999; 822: 237–42.
17. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345: 145–53.
18. Nackley AG, Suplita RL, Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003; 117: 659–70.
19. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 2001; 40: 221–32.
20. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sci 1999; 65: 665–73.
21. Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, et al Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52: 483–6.
22. Notcutt W, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharm Sci 1997; 3: 551–5.
23. Hamann W, di Vadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999; 353: 560.
24. Noyes RJ, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15: 139–43.
25. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21: 320–36S.
26. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106: 169–72.
27. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757–62.
28. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21–29.
29. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517–26.
30. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al New iagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–31.
31. Merskey H, Bogduk N,eds. Classification of chronic pain: descriptions of chronic pain synromes and definitions of parin terms prepare by the international Association for the Study of Pain, Task Force of Taxonomy. Seattle: IASP Press, 1994.
32. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–52.
33. Goldberg JM, Lindblom U. Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry 1979; 42: 793–803.
34. Jensen TS, Bach FW, Kastrup J, Dejgaard A, Brennum J. Vibratory and thermal thresholds in diabetics with and without clinical neuropathy. Acta Neurol Scand 1991; 84: 326–33.
35. Brennum J, Kjeldsen M, Jensen K, Jensen TS. Measurements of human pressure-pain thresholds on fingers and toes. Pain 1989; 38: 211–7.
36. Gottrup H, Kristensen AD, Bach FW, Jensen TS. Aftersensations in experimental and clinical hypersensitivity. Pain 2003; 103: 57–64.
37. Bjorner JB, Damsgaard MT, Watt T, Bech P, Rasmussen NK, Kristensen TS, et al. [Danish manual to SF-36.] Copenhagen: Lif, 1997. (In Danish.)
38. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–4.
39. Senn S. Cross-over trials in clinical research. Chichester: John Wiley, 2002.
40. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56: 184–90.
41. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2: 93–113.
42. Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opin Pharmacother 2002; 3: 1411–20.
43. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389–400.
44. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927–34.
45. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000; 88: 287–94.
46. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC,, Staats PG, et al Safety, tolerability, an efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404–7.
47. Clermont-Gnamien S, Atlani S, Attal N, Le MF, Guirimand F, Brasseur L. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain.] Presse Med 2002; 31: 1840–5. (In French.)
48. Noyes RJ, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84–89.
49. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13–6